Cardiac progenitor-derived exosomes protect ischemic myocardium from acute ischemia/reperfusion injury

Chen, Lijuan; Wang, Yingjie; Pan, Yaohua; Zhang, Lan; Shen, Chengxing; Qin, Gangjian; Ashraf, Muhammad; Weintraub, Neal L.; Ma, Genshan; Tang, Yaoliang

doi:10.1016/j.bbrc.2013.01.015

Cited by 311 publications

(252 citation statements)

References 32 publications

Supporting

Mentioning

240

Contrasting

Unclassified

Order By: Relevance

“…Intramyocardial injection of exosomes from murine cardiac progenitor cells (CPCs) reduced apoptosis after ischaemia and reperfusion (Chen et al 2013). In this study, however, exosomes were isolated by precipitation with polyethylene glycol (PEG) (Chen et al 2013), which raises some uncertainty about the effects that the PEG might have itself. In another study EVs were isolated from CPCs derived from atrial appendage explants from patients undergoing heart valve surgery (Barile et al 2014).…”

Section: Evs As a Potential Therapy For Cardiometabolic Diseasementioning

confidence: 98%

Microvesicles and exosomes: new players in metabolic and cardiovascular disease

Lawson¹,

Vicencio²,

Yellon³

et al. 2016

Journal of Endocrinology

281

236

View full text Add to dashboard Cite

The past decade has witnessed an exponential increase in the number of publications referring to extracellular vesicles (EVs). For many years considered to be extracellular debris, EVs are now seen as novel mediators of endocrine signalling via cell-to-cell communication.With the capability of transferring proteins and nucleic acids from one cell to another, they have become an attractive focus of research for different pathological settings and are now regarded as both mediators and biomarkers of disease including cardio-metabolic disease. They also offer therapeutic potential as signalling agents capable of targeting tissues or cells with specific peptides or miRNAs. In this review, we focus on the role that microvesicles (MVs) and exosomes, the two most studied classes of EV, have in diabetes, cardiovascular disease, endothelial dysfunction, coagulopathies, and polycystic ovary syndrome. We also provide an overview of current developments in MV/exosome isolation techniques from plasma and other fluids, comparing different available commercial and non-commercial methods. We describe different techniques for their optical/biochemical characterization and quantitation. We also review the signalling pathways that exosomes and MVs activate in target cells and provide some insight into their use as biomarkers or potential therapeutic agents. In summary, we give an updated focus on the role that these exciting novel nanoparticles offer for the endocrine community.

show abstract

Section: Evs As a Potential Therapy For Cardiometabolic Diseasementioning

confidence: 98%

Microvesicles and exosomes: new players in metabolic and cardiovascular disease

Lawson¹,

Vicencio²,

Yellon³

et al. 2016

Journal of Endocrinology

281

236

View full text Add to dashboard Cite

show abstract

“…Chen et al (33) reported that mouse CPC exosomes inhibited cardiomyocyte apoptosis in mouse hearts after IR in vivo. Gray et al (34) described proangiogenic and antifibrotic activities of mouse CPC exosomes in vitro.…”

Section: Visualization Of Exosome Release From Cpcsmentioning

confidence: 99%

Beneficial effects of exosomes secreted by cardiac-derived progenitor cells and other cell types in myocardial ischemia

Barile¹,

Milano²,

Vassalli³

2017

Stem Cell Investig.

View full text Add to dashboard Cite

When injected into acutely infarcted rodent or pig hearts, naturally secreted nanovesicles known as exosomes from cardiac-derived progenitor cells (CPCs) reduce scar size and improve cardiac function. In this regard, exosomes fully mimic the benefits of injecting their parent cells. This recognition paves the way to the development of exosome-based, cell-free treatments for heart disease that could possibly supplant cellbased therapies. Mechanisms of benefit of these vesicles are incompletely understood but cytoprotection, stimulation of angiogenesis, induction of antifibrotic cardiac fibroblasts, and modulation of M1/M2 polarization of macrophages infiltrating the infarcted region can all play important roles. Accordingly, the beneficial molecules carried by CPC-secreted exosomes have been identified only in part but cytoprotective and proangiogenic microRNAs (miRNA) and proteins have been described. Besides CPC-secreted exosomes, vesicles released from other cell types including mesenchymal stem cells (MSCs), embryonic stem cells (ESCs), and induced pluripotent stem cells (iSPCs) have also been associated with cardioprotection. This review aims to discuss recent advances in our understanding of the role of secreted vesicles in cardiac repair, with a focus on CPC-derived exosomes.

show abstract

“…59 On a practical note, in experiments such as these, it is important that cells are cultured in serum that has been depleted of exosomes (by ultracentrifugation, for example). Second, it is essential to compare cardioprotection against vehicle containing any carrier retained during purification because, from our experience, vehicles such as bovine serum albumin or polyethylene glycol at high concentration can cause an apparent decrease in infarct size.…”

Section: Exosomes and Cardioprotectionmentioning

confidence: 99%